8-K: Ovid Therapeutics Secures $7 Million Non-Dilutive Capital by Selling Ganaxolone Royalties to Immedica Pharma

Ovid Therapeutics Inc. announced the sale of its future ganaxolone royalty obligations to Immedica Pharma AB for $7.0 million in cash, providing non-dilutive funding and transferring intellectual property costs.

Summary

• Ovid Therapeutics Inc. entered into Amendment No. 1 to its Exclusive Patent License Agreement with Immedica Pharma, AB (which acquired Marinus Pharmaceuticals, Inc. in February 2025).
• Under the First Amendment, Immedica purchased Ovid's ongoing royalty obligations related to ganaxolone sales for $7.0 million in cash.
• The $7.0 million payment is due within 10 business days following the First Amendment Effective Date of June 23, 2025.
• This transaction provides Ovid with a non-dilutive capital infusion, extending its operational runway.
• In 2024, Ovid recorded approximately $566,000 in ganaxolone royalty revenues.
• Ovid was not actively pursuing the development of ganaxolone, and this transaction has no impact on its current pipeline programs.
• Immedica is also obtaining additional rights to prosecute the licensed patents and will assume financial responsibility for all costs related to the licensed intellectual property once a second amendment is finalized.
• A second amendment is expected within six months to expand the field and territory of the original agreement and include additional patents necessary for ganaxolone exploitation.

Sentiment

Score: 7

Explanation: The transaction is a positive strategic move for Ovid, providing non-dilutive capital and allowing the company to focus on its core pipeline. While not a transformative event, it improves financial stability and operational runway.

Positives

• Provides $7.0 million in non-dilutive capital, strengthening Ovid's financial position.
• Extends Ovid's operational runway, supporting ongoing operations.
• Transfers financial responsibility for ganaxolone intellectual property costs to Immedica, reducing Ovid's expenses.
• Allows Ovid to focus resources and attention on its core pipeline programs (OV329, OV350, OV4071) as it was not developing ganaxolone.

Negatives

• Ovid forfeits any future royalty streams from ganaxolone sales, which amounted to $566,000 in 2024.

Risks

• Uncertainties inherent in the preclinical and clinical development and regulatory approval processes for Ovid's remaining pipeline.
• Risks related to Ovid's ability to achieve its financial objectives.
• The risk that Ovid may not be able to realize the intended benefits of its business strategy.
• Unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions.

Future Outlook

Ovid and Immedica plan to enter into a second amendment within six months to expand the field and territory of the original ganaxolone license agreement. This amendment will also grant Immedica additional rights to any other patents controlled by Ovid that are necessary or reasonably useful for exploiting ganaxolone, with Immedica assuming financial responsibility for all related licensed IP costs once finalized.

Management Comments

• "This transaction provides a non-dilutive capital infusion of $7.0 million to Ovid, which will support the Company’s ongoing operations."
• "Ovid has not been pursuing development of ganaxolone, and the transaction has no impact to the Company’s current pipeline of programs."

Industry Context

This transaction reflects a strategic move common in the biopharmaceutical industry where companies divest non-core assets to secure funding and sharpen their focus on pipeline development. For Immedica, it signifies a strengthening of its commitment to ganaxolone, especially following its acquisition of Marinus Pharmaceuticals, consolidating intellectual property and commercial rights for a key rare disease treatment.

Stakeholder Impact

• Shareholders: Benefit from the non-dilutive capital infusion, which extends the company's operational runway and allows for a more focused investment in its core pipeline, potentially reducing the need for future dilutive financing.
• Employees: Increased stability and security due to extended operational runway and clearer strategic focus.
• Customers (patients): No direct impact on ganaxolone availability or development, as Ovid was not pursuing its development. Immedica's increased commitment to ganaxolone may ensure continued support for the drug.

Next Steps

• Immedica Pharma AB is obligated to pay Ovid Therapeutics $7.0 million in cash within 10 business days following June 23, 2025.
• Ovid Therapeutics intends to file the First Amendment as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.
• Ovid Therapeutics and Immedica Pharma AB are agreeing to enter into a second amendment within six months to expand the field and territory of the original ganaxolone license agreement and include additional necessary patents.

Key Dates

Recommendation

Keywords

Ovid Therapeutics, Immedica Pharma, Ganaxolone, Royalties, Non-dilutive funding, Biopharmaceutical, Rare disease, Patent license, CDKL5 deficiency disorder, CDD, SEC Filing, 8-K